Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
9.77M | 16.94M | 35.42M | 28.28M | 11.26M | Gross Profit |
4.31M | -12.74M | 7.21M | 4.27M | -2.37M | EBIT |
-22.33M | -18.89M | 2.97M | 1.56M | -4.83M | EBITDA |
-19.82M | -13.14M | 4.70M | 3.22M | -1.70M | Net Income Common Stockholders |
-17.86M | -14.05M | 3.06M | 1.76M | -2.09M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
36.25M | 16.35M | 36.90M | 30.12M | 31.18M | Total Assets |
67.29M | 49.08M | 59.65M | 54.05M | 49.72M | Total Debt |
1.22M | 0.00 | 34.00K | 399.00K | 741.00K | Net Debt |
-35.03M | -16.35M | -36.86M | -29.72M | -30.43M | Total Liabilities |
6.18M | 6.16M | 4.85M | 4.71M | 3.79M | Stockholders Equity |
61.10M | 42.91M | 54.80M | 49.34M | 45.93M |
Cash Flow | Free Cash Flow | |||
-14.91M | -20.54M | 6.82M | -784.00K | -11.84M | Operating Cash Flow |
-10.12M | -12.45M | 9.81M | 4.20M | -9.49M | Investing Cash Flow |
-4.79M | -8.09M | -2.99M | -4.98M | -2.35M | Financing Cash Flow |
34.81M | -23.00K | -101.00K | -190.00K | 36.69M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $9.91B | 193.11 | 14.52% | ― | 55.85% | 893.42% | |
54 Neutral | AU$204.99M | ― | -37.20% | ― | ― | 32.02% | |
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
45 Neutral | AU$113.57M | ― | -47.52% | ― | 44.61% | 16.40% | |
44 Neutral | AU$51.76M | ― | -131.55% | ― | 12.53% | -11.04% | |
42 Neutral | AU$29.64M | ― | -104.23% | ― | ― | -17.26% | |
37 Underperform | $179.21M | ― | -99.05% | ― | ― | -34.09% |
Genetic Signatures Ltd reported a significant 71% increase in quarterly sales, reaching $2.9 million, driven by high respiratory testing rates in Australia. The company signed its first US commercial contract for its EasyScreen™ Gastrointestinal Parasite Detection Kit and is implementing a new strategy for automated, high throughput solutions through the customization of commercially available instruments. With a strong cash balance of $37.4 million, Genetic Signatures is well-positioned to expand its market presence, particularly in the US, following FDA clearance. The company continues to focus on innovation in assay development, workflow enhancements, and software improvements to support its growth strategy.
Genetic Signatures Ltd. announced the cessation of 380,000 securities due to the lapse of conditional rights, as the conditions for these securities were not met or became unfeasible. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s future financial strategies.
Genetic Signatures Ltd. reported a significant 136% increase in sales for the first half of FY25, reaching $8.5 million, driven by strong respiratory sales in Australia. The company improved its gross margin to 59% and reduced its underlying loss by 20% compared to the previous year. Despite a statutory loss of $15.2 million due to a $6.8 million impairment expense, Genetic Signatures secured its first US commercial contract, marking a strategic expansion into the US market. The company has shifted its strategic direction towards developing a more cost-effective and faster-to-market automated solution, ceasing the development of its Next Generation instrument. This new approach is expected to enhance its syndromic infectious disease testing capabilities, leveraging its 3base technology.
Genetic Signatures Limited reported a 136% increase in revenues to $8,499,000 for the half-year ending December 31, 2024, despite a 45% rise in losses to $15,200,000 compared to the previous year. The significant revenue growth highlights the company’s expanding market presence, although the increased losses suggest ongoing financial challenges, impacting stakeholder confidence and future strategic decisions.